Compare AXIL & GLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AXIL | GLTO |
|---|---|---|
| Founded | 2015 | 2011 |
| Country | United States | Denmark |
| Employees | 10 | N/A |
| Industry | Package Goods/Cosmetics | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 46.1M | 54.5M |
| IPO Year | N/A | 2020 |
| Metric | AXIL | GLTO |
|---|---|---|
| Price | $6.80 | $23.07 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $36.00 |
| AVG Volume (30 Days) | ★ 1.5M | 112.3K |
| Earning Date | 01-06-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.15 | N/A |
| Revenue | ★ $27,262,468.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $46.73 | ★ N/A |
| Revenue Growth | ★ 0.07 | N/A |
| 52 Week Low | $3.75 | $2.01 |
| 52 Week High | $10.75 | $38.33 |
| Indicator | AXIL | GLTO |
|---|---|---|
| Relative Strength Index (RSI) | 50.70 | 46.54 |
| Support Level | $6.55 | $21.56 |
| Resistance Level | $7.85 | $38.33 |
| Average True Range (ATR) | 0.86 | 4.26 |
| MACD | -0.14 | -1.05 |
| Stochastic Oscillator | 7.61 | 9.01 |
AXIL Brands Inc is a company which is is a manufacturer and marketer of premium hearing enhancement and protection products, including ear plugs, earmuffs, and ear buds, and outdoor speakers, under the AXIL brand. AXIL delivers top hearing enhancement, protection, & audio devices. From ultra comfortable fitting processes, to stereo quality sound performance, to reliable & durable engineering. The company operates two operating segments: hearing enhancement and protection, and hair and skin care.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.